| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTTG1IP |
| Uniprot No | P53801 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-180aa |
| 氨基酸序列 | MAPGVARGPTPYWRLRLGGAALLLLLIPVAAAQEPPGAACSQNTNKTCEECLKNVSCLWCNTNKACLDYPVTSVLPPASLCKLSSARWGVCWVNFEALIITMSVVGGTLLLGIAICCCCCCRRKRSRKPDRSEEKAMREREERRIRQEERRAEMKTRHDEIRKKYGLFKEENPYARFENN |
| 预测分子量 | 20,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTTG1IP重组蛋白的3篇参考文献及其摘要内容：
---
1. **文献名称**: *"Purification and functional characterization of recombinant human PTTG1IP reveals its role in cell migration"*
**作者**: Smith A, et al.
**摘要**: 该研究成功在大肠杆菌中表达了重组人源PTTG1IP蛋白，并通过亲和层析纯化获得高纯度蛋白。功能实验表明，PTTG1IP通过调控整合素信号通路促进肿瘤细胞的迁移能力，提示其在癌症转移中的潜在作用。
---
2. **文献名称**: *"Structural analysis of PTTG1IP using X-ray crystallography and its interaction with PTTG1"*
**作者**: Lee JH, Kim S.
**摘要**: 作者解析了重组PTTG1IP蛋白的晶体结构，揭示了其与PTTG1(垂体肿瘤转化基因1)结合的特定结构域。实验证实两者结合后共同激活MAPK通路，为靶向该相互作用的抗癌药物设计提供了结构基础。
---
3. **文献名称**: *"Development of a mammalian expression system for bioactive PTTG1IP and its role in angiogenesis"*
**作者**: Chen L, et al.
**摘要**: 研究利用哺乳动物细胞(HEK293)系统表达具有生物活性的重组PTTG1IP蛋白，并发现其通过上调VEGF分泌促进血管生成。该成果为研究PTTG1IP在肿瘤微环境中的功能提供了工具。
---
**备注**：以上文献信息为示例性内容，实际文献需通过PubMed或Web of Science等平台检索确认。若需具体文献，建议使用关键词“PTTG1IP/PBF recombinant protein”进一步筛选。
**Background of PTTG1IP Recombinant Protein**
PTTG1IP (Pituitary Tumor-Transforming Gene 1 Interacting Protein), also known as PBF (PTTG1-Binding Factor), is a multifunctional protein initially identified through its interaction with PTTG1 (pituitary tumor-transforming gene 1), an oncogene implicated in cell cycle regulation, DNA repair, and tumorigenesis. PTTG1IP is encoded by the *PTTG1IP* gene located on human chromosome 21q22.3 and is evolutionarily conserved across species, underscoring its biological significance.
Structurally, PTTG1IP contains a transmembrane domain and multiple phosphorylation sites, suggesting roles in signal transduction and protein-protein interactions. It binds directly to PTTG1. modulating its subcellular localization and stability. This interaction is critical for PTTG1’s oncogenic activity, including promoting mitotic errors, chromosomal instability, and angiogenesis. Beyond its partnership with PTTG1. PTTG1IP independently regulates cellular processes such as proliferation, migration, and apoptosis. Dysregulation of PTTG1IP has been linked to various cancers, including thyroid, breast, and colorectal carcinomas, where its overexpression correlates with aggressive tumor behavior and poor prognosis.
Recombinant PTTG1IP protein is engineered for research applications, typically produced in *E. coli* or mammalian expression systems to ensure proper folding and post-translational modifications. It serves as a tool for studying PTTG1IP’s molecular functions, screening therapeutic agents targeting PTTG1/PTTG1IP pathways, and developing antibodies for diagnostic assays. Recent studies also explore its potential as a biomarker or therapeutic target, particularly in cancers driven by PTTG1 signaling. However, the precise mechanisms of PTTG1IP in tumorigenesis and its broader physiological roles remain under investigation, highlighting the need for further functional and structural characterization.
In summary, PTTG1IP recombinant protein provides a valuable resource for dissecting the oncogenic network of PTTG1 and advancing translational research in cancer biology.
×
